Skip to main content
Swing Capital

Viyash Scientific Ltd

NSE: VIYASH BSE: 512529Pharma

Sequent Scientific is India's leading animal health company, with presence in 5+ continents across 100 countries. Sequent Scientific Limited provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.

₹225
52W: ₹166 — ₹260
PE 265 · Book ₹27.1 · +730% vs book
Market Cap₹9,855 Cr
Stock P/E265Price to Earnings
ROCE2.4%Return on Capital
ROE1.53%Return on Equity
Div. Yield0%Face Value ₹2

Strengths

  • +Company has reduced debt.
  • +Company is almost debt free.
  • +Company is expected to give good quarter

Weaknesses

  • −Stock is trading at 8.26 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −The company has delivered a poor sales growth of -4.75% over past five years.
  • −Company has a low return on equity of 0.41% over last 3 years.
  • −Debtor days have increased from 86.8 to 141 days.
  • −Working capital days have increased from 26.9 days to 64.5 days

Shareholding Pattern

Promoters61.31%
FIIs2.94%
DIIs7.98%
Public27.67%
CategoryJun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026
Promoters52.78%52.76%▼0.052.61%▼0.152.61%52.61%52.33%▼0.361.41%▲9.161.31%▼0.1
FIIs5.69%6.45%▲0.86.1%▼0.46.05%▼0.06.15%▲0.15.9%▼0.33.16%▼2.72.94%▼0.2
DIIs8.06%9.99%▲1.912.01%▲2.012.82%▲0.812.98%▲0.212.91%▼0.17.36%▼5.57.98%▲0.6
Public33.3%30.63%▼2.729.12%▼1.528.36%▼0.828.1%▼0.328.69%▲0.627.97%▼0.727.67%▼0.3

Financial Statements

MetricSep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025
Sales49.1242.2136.7757.6741.99338.0542.3341.07339.75341.64
Expenses56.8246.3642.5359.6544.09279.7745.1543.11287.7271.3
Operating Profit-7.7-4.15-5.76-1.98-2.158.28-2.82-2.0452.0570.34
OPM %-15.68%-9.83%-15.66%-3.43%-5%17.24%-6.66%-4.97%15.32%20.59%
Net Profit-0.924.583.764.54.2651.134.233.3722.84-0.08
EPS ₹-0.040.180.150.180.172.040.170.130.910

AI Insights

Revenue Trend

TTM revenue at ₹765Cr, up 329.8% YoY. OPM at 15%.

Debt Position

Borrowings at ₹23Cr. Debt-to-equity ratio: 0.02x. Healthy balance sheet.

Capex Cycle

CWIP at ₹1Cr (2% of fixed assets). Moderate ongoing capital expenditure.

Institutional Flow

DIIs: 7.98% (+5.06pp change). FIIs: 2.94% (-3.33pp change). Promoters hold 61.31%.

Margin & Efficiency

ROCE improving from -6% (Mar 2014) to 2% (Mar 2025). Working capital days: 64.

Valuation

PE 265x with 2.4% ROCE. Price is 730% above book value of ₹27.1. Dividend yield: 0%.

Recent Announcements